Saturday, November 21, 2015 10:16:03 AM
Look at the daily chart, and the August 24th price action showed strong accumulation of stock that lead to a strong 11 day rally up nearly 100%. Yesterdays ,11-20-15, price action accumulation was the same and with the fantastic news of a successful spinal cord nerve repair and actual improvement in movement in human test subjects, this is the turning point for Stem Cells Inc.
I truly believe that this move could be 400 to 500 percent.
Here is the story November 18, 2015 4:05 PM GlobeNewswire, StemCells Presents Six-Month Interim Results from Pathway Study- StemCells (NASDAQ:STEM) presented six-month interim results from the first cohort in the Pathway Study, a Phase II proof-of-concept study evaluating the company's HuCNS-SC platform in cervical spinal cord injury. The company reported that dose of 40M cells was well tolerated and will be the dose for the second cohort. The company also said that safety profile is acceptable. In addition, five of the six patients that were part of the first cohort demonstrated improved upper extremity muscle strength and four patients demonstrated improved function in dexterity. The final results from the cohort are expected to be released in the second quarter of 2016.
Visit Stem Cells Inc. video page to watch the eye opening research and testimonies.
http://www.stemcellsinc.com/News-Events/Video-Library
Bio tec news today. 11-21-15, Stem Cells Inc.
Recent STEM News
- Stem Announces PowerTrack™ APM for Comprehensive Solar and Storage Energy Portfolio Management • Business Wire • 05/02/2024 08:10:00 PM
- Stem Announces First Quarter 2024 Results • Business Wire • 05/02/2024 08:05:00 PM
- Stem Announces Appointment of AI Industry Leader as New Independent Director • Business Wire • 04/19/2024 08:30:00 PM
- Stem Announces First Quarter 2024 Earnings Results Conference Call • Business Wire • 04/16/2024 12:30:00 PM
- Stem’s PowerBidder™ Pro Selected by Two CCAs in CAISO • Business Wire • 03/19/2024 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2024 02:24:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:43:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:36:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:36:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:35:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:34:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:34:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:33:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 10:04:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:25:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:25:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:23:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:23:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:23:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:22:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:22:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:20:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 05:18:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 01:27:52 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 01:26:31 AM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM